OrbiMed Advisors

From biopharmaceuticals to medical devices, diagnostics, and healthcare services, OrbiMed is scouting the globe for innovations that will help ensure humanity lives healthier, longer and more productive lives.

We have been investing globally for over 20 years across the healthcare industry: from early-stage private companies to large multinational corporations. Our team of over 80 distinguished scientific, medical, investment and other professionals manage approximately $14 billion across public and private company investments worldwide.

Type
Investor
HQ
New York, US
Founded
1989
OrbiMed Advisors was founded in 1989 and is headquartered in New York, US

OrbiMed Advisors Office Locations

OrbiMed Advisors has an office in New York
New York, US (HQ)
601 Lexington Ave

OrbiMed Advisors Investment Portfolio

Stage Distribution

Top Sectors Distribution

Round Size Distribution

OrbiMed Advisors News and Updates

Cyrus Biotechnology Announces $8M Financing to Expand Computational Drug Discovery Software Platform

PRESS RELEASE: Cyrus Biotechnology, Inc., a Seattle-based biotechnology software firm offering an advanced computational tool for protein modeling and design to accelerate new drug discovery, today announced the closing of an $8M total Series A financing....

Where Pharmacy Giants Walgreens, CVS, Walmart, And Rite Aid Are Placing Private Market Bets

For many consumers, the local pharmacy is long gone, replaced by big box retailers with significantly more cash and brand recognition. The top four retail pharmacies, by number of stores —Walmart, Walgreens, CVS and Rite Aid — operate more than … Continued

The Race To Acquire Medical Device Startups In One Graphic

Medical device startups across the globe raised nearly $4B in equity financing in 2016, placing last year just behind the 5-year high of $4.1B in 2014. NEA stands out as the most active investor in device startups with Versant Ventures, OrbiMed Advisors, and High-Tech … Continued

Unicorn Outcomes: Sequoia Capital Sees The Most $1B+ Exits And Tends To Get In Early

There have been 141 exits of private companies globally valued at $1B+ from 2009 through 3/27/2017. We define a “unicorn exit” as a merger, acquisition, or IPO of a VC-backed company in which the valuation at exit is $1B+, regardless … Continued

The Top 100 Venture Capitalists

For the second year in a row, we worked with The New York Times to identify and rank the top 100 venture capital professionals using the CB Insights Investor Mosaic algorithm. In a purely data-driven / algorithmic ranking, we used CB Insights data, gathered via … Continued

Grapeless Wine And Cowless Milk: 60+ Synthetic Biology Startups In A Market Map

Over the past five years, funding to synthetic biology startups has more than tripled, surpassing the $1B mark for the first time in 2016. Deal flow has also grown significantly, up over 150% since 2012. We define synthetic biology as … Continued
Show more

Traffic Overview of OrbiMed Advisors

OrbiMed Advisors Company Life and Culture